Rhinitis, Allergic, Seasonal

鼻炎,过敏,季节性
  • 文章类型: Journal Article
    背景:过敏和癌症之间的联系是矛盾的,而某些形式的癌症与过敏呈负相关。变应性鼻炎(AR)是最常见的变态反应,肺癌是死亡率最高的最常见的癌症之一。最近的研究报道了哮喘和肺癌之间的正相关;然而,这种联系是没有定论的。此外,AR与哮喘呈正相关;因此,我们的研究问题是探讨AR与肺癌的流行病学相关性.
    方法:经过对PubMed的严格搜索,谷歌学者,和科学直接,本系统综述和荟萃分析纳入了7篇符合条件的文章,包括4724例病例和9059例对照,5来自美国,加拿大和德国各一名。
    结果:汇集分析(或,0.55;95%CI:0.45-0.68;P值<.00001)显示AR与肺癌之间呈强烈的负相关。
    结论:目前的荟萃分析提示AR与肺癌呈负相关;然而,需要新的流行病学研究来更全面地观察当前的情景。
    BACKGROUND: The association between allergies and cancer is contradictory, whereas some forms of cancer have inverse associations with allergies. Allergic rhinitis (AR) is the most prevalent form of allergy, and lung cancer is one of the most prevalent forms of cancer with the highest mortality rate. Recent studies have reported a positive association between asthma and lung cancer; however, this association is inconclusive. Furthermore, AR is positively associated with asthma; therefore, our research question was to explore whether there is any correlation between AR and lung cancer epidemiologically.
    METHODS: After a rigorous search of PubMed, Google Scholar, and ScienceDirect, 7 eligible articles were included in this systematic review and meta-analysis, including 4724 cases and 9059 controls, 5 from the USA, and one each from Canada and Germany.
    RESULTS: Pooled analysis (OR, 0.55; 95% CI: 0.45-0.68; P value < .00001) showed a strong inverse relationship between AR and lung cancer.
    CONCLUSIONS: The current meta-analysis suggests an inverse relationship between AR and lung cancer; however, new epidemiological studies are required to observe the current scenario more comprehensively.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Systematic Review
    背景:关于单独鼻内药物治疗过敏性鼻炎(AR)的有效性的系统证据不足。
    目的:进行系统评价,比较单独的鼻内糖皮质激素和抗组胺药与安慰剂在改善常年性或季节性AR患者的鼻和眼部症状以及与鼻结膜炎相关的生活质量方面的疗效。
    方法:我们检索了4个电子书目数据库和3个临床试验数据库中的随机对照试验(i)评估季节性或常年性AR的成年患者,以及(ii)比较鼻内使用糖皮质激素或抗组胺药与安慰剂的比较。评估结果包括总鼻部症状评分(TNSS),总眼部症状评分(TOSS)和鼻结膜炎生活质量问卷(RQLQ)。我们对每种药物和结果的平均差异进行了随机效应荟萃分析。我们使用分级方法评估了证据的确定性。
    结果:我们纳入了151项主要研究,其中大多数评估了季节性AR患者,并显示出不清楚或高偏倚风险。在常年和季节性AR中,大多数评估治疗比安慰剂更有效.在季节性AR中,氮卓斯汀-氟替卡松,糠酸氟替卡松和丙酸氟替卡松是导致TNSS和RQLQ中度或大幅改善的可能性最高的药物.氮卓斯汀-氟替卡松显示出导致TOSS中度或大幅改善的最高可能性。总的来说,在6/46分析中,证据确定性被认为是“高”,23/46分析中的“中等”,和“低”/“非常低”在17/46分析。
    结论:大多数鼻内用药可有效改善鼻炎症状和生活质量。然而,相关证据的确定性存在相关差异。
    BACKGROUND: There is insufficient systematized evidence on the effectiveness of individual intranasal medications in allergic rhinitis (AR).
    OBJECTIVE: We sought to perform a systematic review to compare the efficacy of individual intranasal corticosteroids and antihistamines against placebo in improving the nasal and ocular symptoms and the rhinoconjunctivitis-related quality of life of patients with perennial or seasonal AR.
    METHODS: The investigators searched 4 electronic bibliographic databases and 3 clinical trials databases for randomized controlled trials (1) assessing adult patients with seasonal or perennial AR and (2) comparing the use of intranasal corticosteroids or antihistamines versus placebo. Assessed outcomes included the Total Nasal Symptom Score, the Total Ocular Symptom Score, and the Rhinoconjunctivitis Quality-of-Life Questionnaire. The investigators performed random-effects meta-analyses of mean differences for each medication and outcome. The investigators assessed evidence certainty using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach.
    RESULTS: This review included 151 primary studies, most of which assessed patients with seasonal AR and displayed unclear or high risk of bias. Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, fluticasone furoate, and fluticasone propionate were the medications with the highest probability of resulting in moderate or large improvements in the Total Nasal Symptom Score and Rhinoconjunctivitis Quality-of-Life Questionnaire. Azelastine-fluticasone displayed the highest probability of resulting in moderate or large improvements of Total Ocular Symptom Score. Overall, evidence certainty was considered \"high\" in 6 of 46 analyses, \"moderate\" in 23 of 46 analyses, and \"low\"/\"very low\" in 17 of 46 analyses.
    CONCLUSIONS: Most intranasal medications are effective in improving rhinitis symptoms and quality of life. However, there are relevant differences in the associated evidence certainty.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    近几十年来,过敏相关疾病已成为世界发展中地区日益关注的领域,包括非洲。全球过敏性疾病的患病率已增长到估计的2.62亿哮喘,4亿用于过敏性鼻炎(或花粉热),1.71亿患有特应性皮炎(或湿疹),超过2亿的食物过敏。在非洲,整个大陆的患病率数据存在相当大的变异性,区域,和研究网站水平。此外,在非洲许多农村地区和不发达国家进行的研究仍然有限,目前,几乎没有做什么来表征和绘制混淆研究工作的极其异质的文献。这项范围审查将寻求确定检查患病率的研究,管理策略,结果,以及非洲过敏相关疾病的相关危险因素。将遵循乔安娜·布里格斯研究所的范围审查方法,使用系统审查和Meta分析的首选报告项目扩展范围审查(PRISMA-ScR)编写方案。四个数据库(Embase,全球卫生,PubMed,非洲在线期刊)将搜索2003年至2023年以任何语言发表的文献。标题和摘要筛选和全文筛选将由两名独立审稿人使用Covidence完成;冲突由第三名审稿人解决。数据将由两名审阅者独立使用Covidence提取。报告结果,我们将遵循PRISMA-ScR清单,并报告描述性统计数据和叙述性摘要。
    During recent decades, allergy related diseases have emerged as a growing area of concern in developing regions of the world, including Africa. Worldwide prevalence of allergic diseases has grown to an estimated 262 million for asthma, 400 million for allergic rhinitis (or hay fever), 171 million with atopic dermatitis (or eczema), and over 200 million for food allergy. In Africa, considerable variability exists in the data surrounding prevalence at the continent-wide, regional, and study site levels. Furthermore, research conducted in many rural areas and underdeveloped countries in Africa remains limited, and presently, little has been done to characterize and map the extremely heterogeneous body of literature which confounds research efforts. This scoping review will seek to identify studies examining the prevalence, management strategies, outcomes, and associated risk factors for allergy related diseases in Africa. The Joanna Briggs Institute\'s scoping review methods will be followed, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Review (PRISMA-ScR) was used for writing the protocol. Four databases (Embase, Global Health, PubMed, African Journals Online) will be searched for literature published from 2003 to 2023 in any language. Title and abstract screening and full-text screening will be completed by two independent reviewers using Covidence; conflicts resolved by a third reviewer. Data will be extracted using Covidence by two reviewers independently. To report the results, we will follow the PRISMA-ScR checklist and report descriptive statistics and a narrative summary.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目前对空气过敏原过敏患病率的上升尚不完全理解,并归因于与环境变化和生活方式变化的相互作用。环境氮污染可能是这种患病率增加的潜在驱动因素。虽然过量氮污染的生态影响已被广泛研究,并且相对较好地理解,它对人类过敏的间接影响尚不清楚。氮污染可以以多种方式影响环境,包括空气,土壤,和水。我们的目标是提供氮驱动对植物群落影响的文献综述,植物生产力,和花粉特性以及它们如何导致过敏负担的变化。我们纳入了调查氮污染之间关联的原始文章,花粉,和过敏,在2001年至2022年间发表在国际同行评审期刊上。我们的范围审查发现,大多数研究集中在大气氮污染及其对花粉和花粉过敏原的影响,引起过敏症状.这些研究经常检查多种大气污染物的影响,而不仅仅是氮,这使得很难确定氮污染的具体影响。有一些证据表明,大气氮污染通过增加大气花粉水平来影响花粉过敏,改变花粉结构,改变过敏原结构和释放,并导致变应原反应性增加。关于土壤和水氮污染对花粉致敏性的影响的研究有限。需要进一步的研究来填补目前有关氮污染对花粉及其相关过敏性疾病负担的影响的知识空白。
    The current rise in the prevalence of allergies to aeroallergens is incompletely understood and attributed to interactions with environmental changes and lifestyle changes. Environmental nitrogen pollution might be a potential driver of this increasing prevalence. While the ecological impact of excessive nitrogen pollution has been widely studied and is relatively well understood, its indirect effect on human allergies is not well documented. Nitrogen pollution can affect the environment in various ways, including air, soil, and water. We aim to provide a literature overview of the nitrogen-driven impact on plant communities, plant productivity, and pollen properties and how they lead to changes in allergy burden. We included original articles investigating the associations between nitrogen pollution, pollen, and allergy, published in international peer-reviewed journals between 2001 and 2022. Our scoping review found that the majority of studies focus on atmospheric nitrogen pollution and its impact on pollen and pollen allergens, causing allergy symptoms. These studies often examine the impact of multiple atmospheric pollutants and not just nitrogen, making it difficult to determine the specific impact of nitrogen pollution. There is some evidence that atmospheric nitrogen pollution affects pollen allergy by increasing atmospheric pollen levels, altering pollen structure, altering allergen structure and release, and causing increased allergenic reactivity. Limited research has been conducted on the impact of soil and aqueous nitrogen pollution on pollen allergenic reactivity. Further research is needed to fill the current knowledge gap about the impact of nitrogen pollution on pollen and their related allergic disease burden.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    草花粉是许多国家过敏的主要原因,尤其是欧洲。尽管对草花粉产生和传播的许多要素进行了很好的研究,在空气中占主导地位的草种周围仍然存在差距,其中哪些最有可能引发过敏。在这篇全面的综述中,我们通过探索植物生态学之间的跨学科相互依存关系来分离草花粉过敏的物种方面,公共卫生,空气生物学,生殖物候和分子生态学。我们进一步确定了当前的研究空白,并为未来的研究提供了开放式的问题和建议,以期使研究界集中精力开发新的策略来对抗草花粉过敏。我们强调分离温带和亚热带草的作用,通过进化史上的分歧确定,气候适应和开花时间。然而,两组患者的过敏原交叉反应性和IgE连接程度仍然是一个活跃的研究领域。进一步强调了通过生物分子相似性鉴定过敏原同源性的未来研究的重要性,以及与物种分类学的联系以及这对过敏原性的实际影响。我们还讨论了eDNA和分子生态技术的相关性(DNA元编码,qPCR和ELISA)是定量生物圈与大气之间联系的重要工具。通过更多地了解物种特异性大气eDNA与开花物候之间的联系,我们将进一步阐明物种在向大气释放草花粉和过敏原中的重要性以及它们在草花粉过敏中的个体作用。
    Grass pollen is a leading cause of allergy in many countries, particularly Europe. Although many elements of grass pollen production and dispersal are quite well researched, gaps still remain around the grass species that are predominant in the air and which of those are most likely to trigger allergy. In this comprehensive review we isolate the species aspect in grass pollen allergy by exploring the interdisciplinary interdependencies between plant ecology, public health, aerobiology, reproductive phenology and molecular ecology. We further identify current research gaps and provide open ended questions and recommendations for future research in an effort to focus the research community to develop novel strategies to combat grass pollen allergy. We emphasise the role of separating temperate and subtropical grasses, identified through divergence in evolutionary history, climate adaptations and flowering times. However, allergen cross-reactivity and the degree of IgE connectivity in sufferers between the two groups remains an area of active research. The importance of future research to identify allergen homology through biomolecular similarity and the connection to species taxonomy and practical implications of this to allergenicity is further emphasised. We also discuss the relevance of eDNA and molecular ecological techniques (DNA metabarcoding, qPCR and ELISA) as important tools in quantifying the connection between the biosphere with the atmosphere. By gaining more understanding of the connection between species-specific atmospheric eDNA and flowering phenology we will further elucidate the importance of species in releasing grass pollen and allergens to the atmosphere and their individual role in grass pollen allergy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    呼吸系统疾病如哮喘,过敏性鼻炎(AR)和慢性阻塞性肺疾病(COPD)影响全球数百万人,并造成重大的全球公共卫生负担.多年来,土地利用和气候的变化增加了花粉数量,花粉季节的致敏性和持续时间,从而增加其对呼吸道疾病的影响。许多研究已经调查了短期环境花粉(即,在暴露的几天或几周内)和呼吸结果。这里,我们回顾了关于短期室外花粉暴露与雷暴哮喘(TA)之间关联的当前证据,哮喘和COPD医院介绍,全科医生(GP)咨询,自我报告的呼吸道症状,肺功能变化及其潜在的效应调节剂。文献表明,有强有力的证据表明,环境花粉浓度与上述几乎所有呼吸道结局之间存在关联。特别是在患有呼吸系统疾病的人中。然而,亚临床肺功能改变的证据,COPD,和哮喘以外的效应调节剂,花粉热和花粉致敏仍然很少,需要进一步探索。更好地了解花粉对呼吸健康的影响可以帮助医疗保健专业人员实施适当的管理策略。
    Respiratory diseases such as asthma, allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD) affect millions worldwide and pose a significant global public health burden. Over the years, changes in land use and climate have increased pollen quantity, allergenicity and duration of the pollen season, thus increasing its impact on respiratory disease. Many studies have investigated the associations between short-term ambient pollen (i.e., within days or weeks of exposure) and respiratory outcomes. Here, we reviewed the current evidence on the association between short-term outdoor pollen exposure and thunderstorm asthma (TA), asthma and COPD hospital presentations, general practice (GP) consultations, self-reported respiratory symptoms, lung function changes and their potential effect modifiers. The literature suggests strong evidence of an association between ambient pollen concentrations and almost all respiratory outcomes mentioned above, especially in people with pre-existing respiratory diseases. However, the evidence on sub-clinical lung function changes, COPD, and effect modifiers other than asthma, hay fever and pollen sensitisation are still scarce and requires further exploration. Better understanding of the implications of pollen on respiratory health can aid healthcare professionals to implement appropriate management strategies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Meta-Analysis
    局部鼻腔免疫疗法(LNIT),一种替代的非注射免疫疗法,理论上是直接在受影响的器官中诱导免疫耐受的有效方法。LNIT比注射免疫疗法更方便,侵入性更小,系统反应较少。克服LNIT局限性的佐剂的开发提高了其作为替代过敏原免疫疗法的可能性。
    评价LNIT对变应性鼻炎患者的临床和免疫学疗效及安全性。
    使用OVIDMedline和Embase对比较LNIT和安慰剂的随机对照试验进行了系统搜索。结果是鼻部症状总评分(TNSS),症状-药物评分(SMS),药物评分,免疫学评估,和鼻挑衅阈值。数据汇总用于荟萃分析。
    共纳入20项研究,共698名参与者。LNIT组在TNSS治疗后有更大的改善,SMS,和药物评分高于对照组(TNSS:标准化平均差[SMD],-1.37[95%置信区间[CI],-2.04至-0.69];SMS:SMD,-1.55[95%CI,-2.83至-0.28];药物评分:SMD,-1.09[95%CI,-1.35至-0.83])。免疫学评估显示血清特异性IgE没有显着差异(平均差[MD],6.35;95%CI,-4.62至17.31),鼻IgE(MD,-0.59;95%CI,-1.99至0.81),或鼻腔嗜酸性粒细胞阳离子蛋白(MD,7.63;95%CI,-18.65至33.91)。仅血清IgG随LNIT显着增加(MD,0.45;95%CI,0.20,0.70)。后处理,LNIT的鼻激发阈值较高(MD,27.30;95%CI,10.13-44.46)。未报告显著不良事件。
    LNIT是一种安全的替代变应原免疫治疗途径,无明显不良事件。它改善了临床症状,减少药物使用,并增加鼻激发阈值。
    Local nasal immunotherapy (LNIT), an alternative noninjection immunotherapy method, is theoretically an efficient method for inducing immunotolerance directly in the affected organ. LNIT is more convenient and less invasive than injection immunotherapy, with fewer systemic reactions. The development of adjuvants to overcome LNIT\'s limitations raises the possibility of it being an alternative allergen immunotherapy.
    To evaluate the clinical and immunological efficacy and safety of LNIT for patients with allergic rhinitis.
    A systematic search for randomized controlled trials comparing LNIT and placebo was performed using OVID Medline and Embase. Outcomes were total nasal symptom score (TNSS), symptom-medication score (SMS), medication score, immunological assessment, and nasal provocation threshold. Data were pooled for meta-analysis.
    A total of 20 studies with 698 participants were included. The LNIT group had greater posttreatment improvement in TNSS, SMS, and medication score than control (TNSS: standardized mean difference [SMD], -1.37 [95% confidence interval [CI], -2.04 to -0.69]; SMS: SMD, -1.55 [95% CI, -2.83 to -0.28]; and medication score: SMD, -1.09 [95% CI, -1.35 to -0.83]). Immunological assessments showed no significant differences in serum-specific IgE (mean difference [MD], 6.35; 95% CI, -4.62 to 17.31), nasal IgE (MD, -0.59; 95% CI, -1.99 to 0.81), or nasal eosinophil cationic protein (MD, 7.63; 95% CI, -18.65 to 33.91). Only serum IgG significantly increased with LNIT (MD, 0.45; 95% CI, 0.20, 0.70). Posttreatment, nasal provocation threshold was higher with LNIT (MD, 27.30; 95% CI, 10.13-44.46). No significant adverse events were reported.
    LNIT is a safe alternative allergen immunotherapy route without significant adverse events. It improves clinical symptoms, reduces medication usage, and increases the nasal provocation threshold.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    未经授权:评估类黄酮补充剂对过敏性疾病的临床疗效。
    未经评估:系统评价。数据源。MEDLINE/PubMed,Scopus,WebofScience,和Embase数据库从开始到2021年9月进行了搜索。选择研究的资格标准。合格的研究设计是研究黄酮类化合物应用于过敏性疾病的效果的随机对照试验。
    UNASSIGNED:本综述包括15项随机对照试验,包括过敏性鼻炎/雪松花粉症(n=10),哮喘(n=3),和特应性皮炎(n=2)。共有990名6至69岁的参与者被纳入这些研究。全球范围内,12项研究(80%)揭示了黄酮类化合物(分离或与其他化合物组合)在过敏患者中的一些益处,而三项研究(20%)报告对症状评分和/或肺功能无统计学显著影响。未报告与治疗相关的严重不良事件。根据等级制度,评估的结局为低至中等质量的证据.
    未经评估:总的来说,这篇综述表明,黄酮类化合物的给药可能为减轻过敏症状提供可行的策略。未来需要具有高方法学质量的试验来建立明确的结论。该试验已在PROSPERO注册号上注册。CRD42021237403。
    UNASSIGNED: To assess the clinical efficacy of flavonoid supplements on allergic diseases.
    UNASSIGNED: Systematic review. Data Sources. MEDLINE/PubMed, Scopus, Web of Science, and Embase databases were searched from inception to September 2021. Eligibility Criteria for Selecting Studies. Eligible study designs were randomized controlled trials that investigated the effect of flavonoids applied to allergic diseases.
    UNASSIGNED: This review included 15 randomized controlled trials, including allergic rhinitis/cedar pollinosis (n = 10), asthma (n = 3), and atopic dermatitis (n = 2). A total of 990 participants aged 6 to 69 years were included in these studies. Globally, 12 studies (80%) revealed some benefits of flavonoids (isolate or combined with other compounds) in allergic patients, while three studies (20%) reported no statistically significant impact on symptom scores and/or lung function. No severe adverse events related to treatment were reported. According to the GRADE system, the outcomes evaluated were of low to moderate quality of evidence.
    UNASSIGNED: Overall, this review suggests that the administration of flavonoids may provide a viable strategy for mitigating allergic symptoms. Future trials with high methodological quality are needed to establish definitive conclusions. This trial is registered with PROSPERO registration no. CRD42021237403.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    禾本科由12,000种植物组成。这些物种中的一些会产生高度过敏的嗜风性花粉粒(PG)。毛皮花粉粒(PPPGs)成为与草过敏相关的研究的模型。尽管除了变应原蛋白以外的PG成分具有潜在的健康作用,但变应原性PG的生化组成尚未被充分描述。这篇综述汇集了文献中可获得的信息,旨在全面了解有关提牧草中过敏性PG的化学成分的最新知识。PPPG的平均直径在30-35μm之间,单个PG的质量在11和26ng之间。花粉细胞质充满两种类型的花粉细胞质颗粒(PCG):淀粉颗粒和多糖颗粒(P颗粒)。淀粉颗粒的尺寸为0.6-2.5μm,平均直径为1.1μm(每PG估计有1000个颗粒),而P-颗粒的尺寸为约0.3-0.4μm(每PG估计有61,000-230,000个P-颗粒)。PG的破裂诱导PCG的释放和过敏原在大气气溶胶的可吸入部分中的分散。PPPG由孢子粉蛋白组成,糖,糖多糖,淀粉,糖蛋白(包括过敏原),氨基酸,脂质,类黄酮(包括异鼠李素),各种元素(更丰富的是Si,Mg和Ca),酚类化合物,植物前列腺素,类胡萝卜素(色素)金属和吸附的污染物。PPPG含有大约一百种不同的蛋白质,分子量范围从10到94kDa,等电点为3.5-10.6。在这些蛋白质中,过敏原分为11组,从1到13,其中第1组和第5组的过敏原是Phlp花粉过敏的主要贡献者。通过若干研究定量PPPG中的主要变应原Phlp5,其浓度范围为2.7和3.5μg。在未污染环境中的mg-1。其他过敏原的值在文献中很少;过敏原组Phlp1、2和4仅存在一种定量评估。PPPG的可提取脂质部分估计为总PG质量的1.7-2.2%。PPPG中报告的主要化学脂质家族是:烷烃,烯烃,酒精,饱和和不饱和脂肪酸,二羟基和三羟基脂肪酸,醛和甾醇。已经在PPPG中明确定量了几种对过敏具有潜在辅助作用的脂质化合物:E2样前列腺素(PGE2),B4样白三烯(LTB4),不饱和脂肪酸(亚油酸和亚麻酸及其羟基化衍生物),腺苷,维生素和酚类化合物。一些其他的生化特性,如NAD(P)H氧化酶,文献中描述了蛋白酶活性和花粉微生物组。生理条件下的生物可及性尚未描述大多数通过变应原性PPPG运输的生物化学物质。还相当缺乏关于除过敏原以外的花粉成分的潜在健康影响的知识。花粉组成的变化也仍然很大程度上未知,尽管它在以化学污染为特征的环境中对植物繁殖和过敏很重要。气候变化和生物多样性的丧失。
    The Poaceae family is composed of 12,000 plant species. Some of these species produce highly allergenic anemophilous pollen grains (PGs). Phleum pratense pollen grains (PPPGs) emerged as a model for studies related to grass allergy. The biochemical composition of allergenic PGs has not yet been fully described despite potential health effects of PG constituents other than allergenic proteins. This review brings together the information available in literature aiming at creating a comprehensive picture of the current knowledge about the chemical composition of allergenic PGs from timothy grass. PPPGs have an average diameter between 30-35 μm and the mass of a single PG was reported between 11 and 26 ng. The pollen cytoplasm is filled with two types of pollen cytoplasmic granules (PCGs): the starch granules and the polysaccharide particles (p-particles). Starch granules have a size between 0.6-2.5 μm with an average diameter of 1.1 μm (estimated number of 1000 granules per PG) while p-particles have a size ranging around 0.3 to 0.4 μm (estimated number between 61,000-230,000 p-particles per PG). The rupture of PG induces the release of PCGs and the dispersion of allergens in the inhalable fraction of atmospheric aerosol. PPPGs are composed of sporopollenin, sugars, polysaccharides, starch, glycoproteins (including allergens), amino-acids, lipids, flavonoids (including isorhamnetin), various elements (the more abundant being Si, Mg and Ca), phenolic compounds, phytoprostanoids, carotenoids (pigments) metals and adsorbed pollutants. PPPG contains about a hundred different proteins with molecular masses ranging from 10 to 94 kDa, with isoelectric points from 3.5-10.6. Among these proteins, allergens are classified in eleven groups from 1 to 13 with allergens from groups 1 and 5 being the major contributors to Phl p pollen allergy. Major allergen Phl p 5 was quantified in PPPGs by several studies with concentration ranging from 2.7 and 3.5 μg.mg-1 in unpolluted environment. Values for other allergens are scarce in literature; only one quantitative assessment exists for allergen groups Phl p 1, 2 and 4. The extractible lipid fraction of PPPGs is estimated between 1.7-2.2% of the total PG mass. The main chemical families of lipids reported in PPPGs are: alkanes, alkenes, alcohols, saturated and unsaturated fatty acids, di- and tri-hydroxylated fatty acids, aldehydes and sterols. Several lipid compounds with potential adjuvant effects on allergy have been specifically quantified in PPPGs: E2-like prostaglandin (PGE2), B4-like leukotriene (LTB4), unsaturated fatty acids (linoleic and linolenic acids and their hydroxylated derivatives), adenosine, vitamins and phenolic compounds. Some other biochemical characteristics such as NAD(P)H oxidase, protease activity and pollen microbiome were described in the literature. The bioaccessibility in physiological conditions has not been described for most biochemicals transported by allergenic PPPGs. There is also a considerable lack of knowledge about the potential health effects of pollen constituents other than allergens. The variability of pollen composition remains also largely unknown despite its importance for plant reproduction and allergy in an environment characterized by chemical pollution, climate change and loss of biodiversity.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    Pollen, a major causal agent of respiratory allergy, is mainly affected by weather conditions. In Korea, pollen and weather data are collected by the national observation network. Forecast models and operational services are developed and provided based on the national pollen data base. Using the pollen risk forecast information will help patients with respiratory allergy to improve their lives. Changes in temperature and CO2 concentration by climate change affect the growth of plants and their capacity of producing more allergenic pollens, which should be considered in making the future strategy on treating allergy patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号